Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News


The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments. Immunomedics shares were flying high ahead of the opening bell on Friday, thanks to the announcement of a licensing agreement with Seattle Genetics for its solid tumor therapy candidate.



from Biotech News